.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Merck
Mallinckrodt
QuintilesIMS
Federal Trade Commission
McKinsey
Queensland Health
Baxter
Harvard Business School
Colorcon

Generated: September 26, 2017

DrugPatentWatch Database Preview

VERELAN PM Drug Profile

« Back to Dashboard

What is the patent landscape for Verelan Pm, and what generic Verelan Pm alternatives are available?

Verelan Pm is a drug marketed by Recro Gainesville and is included in one NDA.

The generic ingredient in VERELAN PM is verapamil hydrochloride. There are sixteen drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.

Summary for Tradename: VERELAN PM

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list40
Clinical Trials: see list8
Patent Applications: see list2,156
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:VERELAN PM at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Recro Gainesville
VERELAN PM
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020943-001Nov 25, 1998ABRXYesNo► Subscribe► Subscribe► Subscribe
Recro Gainesville
VERELAN PM
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020943-002Nov 25, 1998ABRXYesNo► Subscribe► Subscribe► Subscribe
Recro Gainesville
VERELAN PM
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020943-003Nov 25, 1998ABRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: VERELAN PM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Recro Gainesville
VERELAN PM
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020943-001Nov 25, 1998► Subscribe► Subscribe
Recro Gainesville
VERELAN PM
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020943-003Nov 25, 1998► Subscribe► Subscribe
Recro Gainesville
VERELAN PM
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020943-002Nov 25, 1998► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for VERELAN PM

Drugname Dosage Strength RLD Submissiondate
verapamil hydrochlorideExtended-release Tablets100 mg and 200 mgVerelan PM7/20/2006
verapamil hydrochlorideExtended-release Tablets300 mgVerelan PM5/19/2006
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
QuintilesIMS
Boehringer Ingelheim
Harvard Business School
Queensland Health
Colorcon
Julphar
Fish and Richardson
Daiichi Sankyo
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot